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S212 Oral PresentationsApproximately 20% of pts (median age 63.5 yrs) with R/R AML
proceeded to HSCT in the CLASSIC I. More pts in the Clo+Ara-
C arm underwent HSCT in CR from study drug. Pts that proceeded
to transplant had a longer OS compared to those who did not. Over-
all, this post-hoc analysis of the CLASSIC I study demonstrated that
subsequent HSCT in elderly pts with R/R AML was feasible and as-
sociatedwith longer survival; though therewas little evidence of a dif-
ferential effect across treatment arms.
Table. Landmark Analysis and Safety Data
Impact of HSCTon Overall
Survival;
HR (95% CI)Overall
(N 5 320)Clo + Ara-C
(N 5 162)Ara-C alone
(N 5 158)Naive estimate 0.30 (0.22, 0.42) – –Landmark analysis
on FAS patients
at 4 months0.59 (0.37, 0.92) – –Landmark analysis
on CR patients
at 4 months– 0.81 (0.40, 1.63) 0.61 (0.23, 1.60)Landmark analysis on CR
patients at 8 months– 0.50 (0.24, 1.01) 0.40 (0.16, 0.99)HSCT-Related Overall Clo + Ara-C Ara-C aloneSafety; n (%) (N 5 66 HSCT) (N 5 34 HSCT) (N 5 32 HSCT)100-day post-HSCT mortality 9 (13.6%) 4 (11.8%) 5 (15.6%)Acute GVHD (All grades) 11 (16.7%) 5 (14.7%) 6 (18.8%)Acute GVHD (Grade $3) 3 (4.5%) 1 (2.9%) 2 (6.3%)Chronic GVHD 1 (1.5%) 1 (2.9%) 0 (0.0%)VOD Complications 1 (1.5%) 0 (0.0%) 1 (3.1%)HSCT, hematopoietic stem cell transplantation; Clo, clofarabine; Ara-C,
cytarabine; FAS, full analysis set; CR, complete remission; GVHD, graft-
vs-host disease; VOD, veno-occlusive disease.25
FLUDARABINE AND CYCLOPHOSPHAMIDE (Flu-Cy) BASED CONDITION-
ING REGIMENS ARE ASSOCIATED WITH EXCELLENT OUTCOMES ESPE-
CIALLY IN LOW RISK PATIENTS WITH SEVERE APLASTIC ANEMIA (SAA)
George, B., Mathews, V., Ahmed, R., Abraham, A., Srivastava, A. Chris-
tian Medical College, Vellore, Tamilnadu, India
One hundred and five patients (68 men and 37 women) with a me-
dian age of 20 years (range: 2 – 53) with SAA underwent relatedHLA
identical stem cell transplantation (HSCT) using a conditioning reg-
imen of Fludarabine (180 mg/m2 over 6 days), Cyclophosphamide
(120 mg/kg over 2 days) 6 Anti- thymocyte globulin (40mg/kg
over 4 days) between 2004 and 2011. Cyclosporine with mini meth-
otrexate was used for GVHD prophylaxis. Graft source included pe-
ripheral blood stem cells (96) or G-CSF stimulated bonemarrow (9).
Patients were classified as high risk at HSCT (62.8%) if they had ac-
tive infection, previous immunosuppressive therapy, . 20 transfu-
sions or previous major bleed.
One hundred patients engrafted (95.2%) at a median time to neu-
trophil engraftment of 13 days (range: 8 – 19) and platelet engraft-
ment of 11 days (range: 7 – 28). The incidence of grade II-IV
acute GVHD was 24% with grade IV GVHD in 6% with chronic
GVHD in 42% of evaluable patients. Ten patients (9.5%) developed
veno-occlusive disease (VOD) of the liver while 5 (4.7%) developed
hemorrhagic cystitis; all respondedwell to supportive therapy. Over-
all incidence of graft failure was 3.8%. The 2 year overall survival is
79.1% with a survival of 97.4% in the low risk group and 68.1% in
the high risk group. This data was superior to a graft failure inci-
dence of 23% and an overall survival of 46.5% in 26 patients who un-
derwent HSCT using Cyclophosphamide based conditioning
protocols. The use of fludarabine and cyclophosphamide as condi-
tioning regimen is associated with very good outcomes in patientswith SAA. These improved results warrant randomized trials with
cyclophosphamide based conditioning regimens.26
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Background:The clonal karyotype is a major risk factor for the suc-
cess of HCT in patients with MDS. Here we tested the relevance of
the new 5-group cytogenetic risk classification and monosomal kar-
yotype (MK) for relapse and survival.
Methods: Results in 1042 patients with MDS (including progres-
sion to AML), 1-75 (median 45) years old, conditioned with
various regimens and transplanted with marrow (52%) or PBPC
(48%) from related (54%) or unrelated (46%) donors were analyzed.
The association of cytogenetics with HCT outcome was examined.
Results: The 3-year probabilities of relapse for the 5-group cate-
gories very good, good, intermediate, poor, and very poor were 8%,
17%, 19%, 26%, and 48%, and overall survival was 46%, 46%,
41%, 37%, and 8%, respectively (see Table for hazard ratios [HR]).
Table.
Proportion Hazard RatioVariable Category MK (%) (HR) /CI P 5MortalityVery good 0/12 (0) 1.06/0.50-2.24 0.89Good 0/455 (0) 1 –Intermediate 2/181 (1) 1.22/0.97-1.52 0.08Poor 33/159 (21) 1.35/1.07-1.69 0.01Very poor 84/108 (78) 3.13/2.47-3.96 <0.0001RelapseVery good 0.49/0.07-3.56 0.48Good 1 –Intermediate 1.38/0.94-2.05 0.10Poor 1.83/1.25-2.68 0.002Very poor 7.46/5.20-10.69 <0.0001The impact of good and intermediate risk (5-group) on mortality
and relapse coincided with IPSS cytogenetic risks ‘‘good’’ (98%)
and ‘‘intermediate’’ (83%) respectively. IPSS ‘‘poor’’ split into
intermediate (13%), poor (50%) and very poor (36%) in the 5-group
classification. Within IPSS ‘‘poor’’, the 5-group category very poor
had worse outcome than the intermediate category (mortality
HR 5 2.82 [1.78-4.46, p\.0001]; relapse HR 5 3.57 [1.85-6.88,
p 5 .0002]). HR for relapse with MK (vs. non-MK) was 5.19
(3.80-7.09; p\0.0001) and for mortality 2.32 (1.88-
2.87;p\0.0001). MK versus non-MK in 5-group poor risk yielded
HRs of 1.62 (1.03-2.54; p 5 0.04) for mortality and 1.68
(0.80-7.53; p 5 0.17) for relapse. Corresponding figures for very
poor risk were 1.17 (0.72-1.90; p 5 0.53) and 2.0 (0.94-4.27; p 5
0.07). Dependent upon cytogenetic risk the 3-year relapse probabil-
ities were 9%-47%, and survival probabilities 81%-15%.
Adjusting for cytogenetics, older age showed a higher rate of mor-
tality (p\.0001), but not relapse (p5 0.87). The risk of mortality de-
creased over the study duration (p\0.0001); it was higher with
unrelated donors than with HLA matched-siblings (HR 5 1.34, p
5 .005), while relapse risk was lower (HR 5 0.74, p 5 .08).
Summary/Conclusions: The new 5-group cytogenetic classifica-
tion improved the 3-group IPSS model (p\0.0001 for survival and
relapse). MK information further refined the risk groups. Overall
HCT outcomes in MDS have improved, but novel approaches are
needed for patients with high risk cytogenetics.
